Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: ABBV.NYSE
Batch: 7
Published: September 20, 2026
AI Advisors: 14

Historical AI Consensus Investment Thesis

AbbVie (ABBV) Stock Forecast and AI Rating

Deep analysis published Sep 21 2026Original pricing snapshot Sep 18 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

NEUTRAL

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

NEUTRAL

$276

+4.7%+7.4% incl. dividends

2031

5-Year

NEUTRAL

$331

+25.3%+42.5% incl. dividends

Published batch insight

Immunology Cash Machine Confronts Scheduled Price Caps and Refinancing Headwinds

Consensus reveals high consensus on commercial dominance across core immunology and neuroscience franchises, generating nearly twenty billion dollars in annual free cash flow. However, sharp divergence exists regarding balance-sheet leverage, debt refinancing burdens, and impending statutory drug pricing cuts under Medicare Part D.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

Warren Buffett (Value Purist), Universal Investor (Polymath), Superintelligence (Anthropologist), Ray Dalio (Strategist), Michael Burry (Vulture), Sherlock Holmes (Whistleblower), J.P. Morgan (Titan), Machiavelli (Insider), Elon Musk (Visionary). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in AbbVie at the forecast anchor (2026-09-18): $14,251 in five years versus $13,892 for S&P 500 benchmark.

AbbVie · Synthesized ConsensusS&P 500 benchmark

* Return is calculated incl. 2.6% net dividend yield for AbbVie.

Figure: Five-year synthesized consensus value path for AbbVie compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView table

Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 263.96 USD1-year price return: +4.67%5-year price return: +25.34%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in USD, with returns and rationale
Quarter	Target (USD)	Quarter return	Total return	Forecast rationale
Q4 2026	266.82	+1.08%	+1.08%	Closing expenses from the Apogee transaction and elevated benchmark yields temper multiple expansion, but robust third-quarter immunology volume and routine dividend increases maintain stable baseline equity demand.
Q1 2027	266.72	-0.04%	+1.05%	Initial 2027 guidance reflects acquired pipeline dilution and statutory Medicare liabilities, prompting mild valuation multiple consolidation despite underlying operational revenue growth across core specialty franchises.
Q2 2027	273.56	+2.56%	+3.64%	First-quarter prescription data shows Skyrizi and Rinvoq capturing expanded market share across gastroenterology, offsetting residual Humira erosion and driving a modest equity recovery.
Q3 2027	276.29	+1.00%	+4.67%	Expanding neuroscience volumes led by migraine therapies and Vyalev provide operational diversification, allowing strong free cash flow generation to absorb broader macroeconomic yield pressures.
Q4 2027	279.76	+1.25%	+5.98%	Management confirms its annual dividend increase, reinforcing defensive dividend credentials as institutional capital seeks shelter from cyclical volatility in cash-generative large-cap biopharma.
Q1 2028	279.27	-0.17%	+5.80%	Negotiated Medicare Part D pricing disclosures and selective gross-to-net rebate compression create temporary headline anxiety, triggering modest valuation multiple contraction across specialty pharmaceutical holdings.
Q2 2028	286.21	+2.48%	+8.43%	Operating results confirm international volume expansion compensates for domestic statutory price cuts, while targeted oncology adoption stabilizes quarterly revenues and restores investor confidence.
Q3 2028	288.99	+0.97%	+9.48%	Clinical pipeline updates across next-generation oncology conjugates and Parkinson's indications support sentiment, though softening consumer discretionary aesthetic volumes restrains broad valuation multiple expansion.
Q4 2028	293.56	+1.58%	+11.21%	Durable operating cash flow enables disciplined debt retirement and another regular dividend enhancement, anchoring intrinsic valuation as the market rewards predictable cash conversion.
Q1 2029	294.60	+0.35%	+11.61%	Anticipation of the approaching 2029 Vraylar loss of exclusivity and initial Medicare price resets for selected therapies moderates quarterly earnings momentum, keeping trading ranges constrained.
Q2 2029	301.19	+2.24%	+14.10%	Expanding commercial adoption of subcutaneous formulations and next-generation oncology indications drives solid operational leverage, supporting a modest, disciplined equity price advance.
Q3 2029	304.12	+0.97%	+15.21%	Steady free cash flow generation above twenty billion dollars annualized facilitates balance sheet de-leveraging, though competitive oral immunology trial data prompts cautious positioning.
Q4 2029	309.18	+1.66%	+17.13%	Defensive institutional allocation into cash-generative healthcare assets supports year-end pricing, while unbroken dividend growth provides an effective floor against macro credit volatility.
Q1 2030	310.02	+0.27%	+17.45%	Consolidated guidance reflects single-digit revenue growth as core immunology franchises reach mature scale, with sell-side models beginning to embed early terminal value discounting.
Q2 2030	316.20	+1.99%	+19.79%	Pivotal clinical progression in acquired late-stage pipelines reaffirms long-term franchise succession, driving selective institutional accumulation as post-2032 operational visibility improves.
Q3 2030	318.75	+0.81%	+20.76%	Commercial execution in solid tumors and mature neuroscience indications delivers steady earnings, offsetting ongoing statutory payer rebate friction during a quiet summer valuation consolidation.
Q4 2030	322.52	+1.18%	+22.19%	Annual capital allocation updates emphasize continued deleveraging and dividend compounding, providing valuation ballast as net debt ratios steadily improve toward conservative targets.
Q1 2031	323.49	+0.30%	+22.55%	Preparations for mid-decade patent expiries across legacy biologic formulations induce modest forward multiple caution, muting quarterly price appreciation despite stable underlying cash flows.
Q2 2031	327.37	+1.20%	+24.02%	Commercial scaling of next-generation immunology and oncology therapies begins backfilling mature revenue lines, reassuring investors regarding structural cash-flow continuity.
Q3 2031	330.85	+1.06%	+25.34%	Five-year horizon closes with the company established as a mature, diversified cash generator, where steady cash distributions and debt amortization balance terminal multiple compression.

AbbVie's core economic thesis rests on an exceptional operational pivot: Skyrizi and Rinvoq have decisively outstripped Humira's historical peak revenue, generating over $31 billion in annualized sales and anchoring consolidated top-line reacceleration. Coupled with a neuroscience pillar expanding past $12 billion, non-cyclical prescription demand generates approximately $19 billion in annual free cash flow. However, valuation sensitivity is acute. Trading near 19 times forward earnings in a 5% sovereign yield regime, the equity prices operational perfection while discounting structural debt obligations exceeding $60 billion and negative accounting equity. The decisive counterargument emphasizes capital allocation friction and regulatory degradation. Mandatory Medicare Part D price negotiations and statutory rebate restructuring will progressively trim domestic gross-to-net realization across mature blockbusters. Concurrently, externalized pipeline replenishment—highlighted by the $10.9 billion Apogee acquisition that accretes only in 2032—consumes free cash, slowing balance-sheet repair and exposing equity valuation to terminal multiple compression.

Key insights

Statutory Medicare maximum fair price implementations directly compress realized domestic gross margins, capping outer-year operating leverage on mature blockbusters.
Serial debt-funded biotech acquisitions replace internal discovery, consuming distributable cash flow and deferring balance-sheet deleveraging into the next decade.
Approaching 2030s loss-of-exclusivity horizons will trigger premature multiple compression well before primary composition-of-matter patents expire.

Deep Dive

The prevailing market consensus treats AbbVie's post-Humira transition as a settled triumph. Investors and sell-side analysts believe Skyrizi and Rinvoq have established an unassailable commercial duopoly that permanently secures double-digit earnings compounding. The crowd prices the stock as an untouchable defensive cash haven and dividend aristocrat, largely dismissing negative book equity, impending Medicare price negotiations, and the costs of replenishing clinical pipelines.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The crowd overestimates the terminal valuation multiple of AbbVie's equity. While the market correctly celebrates the replacement of Humira, its analytical blind spot lies in cash ownership and statutory price erosion. Mandated Medicare Part D discounts, widening commercial PBM rebates, and rising debt refinancing costs will systematically trim net realizations. Furthermore, continuous multi-billion-dollar acquisitions to backfill pipeline gaps dilute near-term earnings, forcing forward multiples to compress toward mature pharmaceutical industry medians.

Repricing catalyst

The convergence catalyst centers on the phased implementation of Medicare Part D maximum fair prices alongside corporate debt refinancing cycles across 2027 and 2028. As statutory pricing discounts take effect and higher interest expenses elevate annual debt service above $3 billion, incremental cash flow conversion will visibly slow. This will force Wall Street analysts to lower terminal growth assumptions and compress forward valuation multiples.

Published consensus context

Macro regime alignment

The macroeconomic backdrop of persistent inflation and Federal Reserve policy rates near 4.0% with five-percent Treasury yields represents a net valuation headwind. While biological demand inelasticity insulates prescription revenues from economic cycles, elevated discount rates mechanically penalize long-duration equity multiples and escalate refinancing costs across AbbVie's substantial gross debt stack, while discretionary aesthetic demand softens under household budget pressure.

Published consensus context

Advisor disagreement

The primary disagreement across reports centers on valuation durability and capital allocation efficiency. Bullish perspectives view Skyrizi and Rinvoq as an impenetrable commercial fortress generating sufficient cash flow to easily outgrow patent expirations, justifying premium multiples near twenty times earnings. Conversely, skeptical analyses emphasize that negative book equity, seventy billion dollars in debt, and rising refinancing yields create severe vulnerability. They argue that externalized M&A pipelines like Apogee dilute near-term cash flow and that statutory Medicare pricing caps will inevitably compress forward multiples toward low-teens historical medians.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

Immunology duo volume supremacy: Skyrizi and Rinvoq have decisively eclipsed Humira's peak revenues, generating over $31 billion in combined annualized sales across expanded indications in psoriasis, arthritis, and inflammatory bowel disease. Superior clinical clearance data and entrenched formulary tiering establish formidable switching barriers. This sustained volume uptake expands operating cash flow, insulating earnings and securing baseline corporate profitability. Expected impact: +26%.
Neuroscience franchise scale diversification: AbbVie's neuroscience division has scaled past $12 billion in annual revenues, driven by Vraylar's expansion into major depression, therapeutic Botox, and CGRP migraine treatments Qulipta and Ubrelvy, alongside Vyalev in Parkinson's disease. Non-cyclical central nervous system demand provides an autonomous growth engine, diversifying cash flows away from sole immunology dependence and bolstering gross profit margins. Expected impact: +16%.
Operating cash flow conversion engine: With physical maintenance capex consistently under two percent of revenue, AbbVie converts approximately thirty percent of gross sales into nearly $20 billion in annual free cash flow. This self-funding capital structure comfortably covers the $11.7 billion annual dividend commitment while enabling disciplined debt amortization. Predictable cash generation anchors institutional demand and establishes a firm intrinsic valuation floor. Expected impact: +14%.
Targeted oncology and ADC expansion: Commercial scaling of antibody-drug conjugates led by Elahere in platinum-resistant ovarian cancer, combined with hematology label expansions for Venclexta and Epkinly, revitalizes AbbVie's oncology segment. These specialized therapies command resilient pricing power with minimal payer pushback, offsetting legacy Imbruvica declines and expanding high-margin commercial revenues across solid tumor oncology markets. Expected impact: +11%.

Top frictions and headwinds

Statutory Medicare drug price negotiation: Inflation Reduction Act provisions mandating Medicare Part D redesign and statutory price negotiation enforce structural gross-to-net realization compression across mature blockbusters. Starting with Imbruvica and expanding to additional core therapies, mandatory manufacturer discounts leak into commercial payer contracts. This administrative pricing squeeze constrains gross margins and permanently caps long-term valuation multiples. Expected impact: -15%.
Balance sheet debt refinancing drag: AbbVie carries negative accounting equity and over $60 billion in gross obligations resulting from historic mega-acquisitions. In a monetary regime where benchmark yields hover near five percent, refinancing maturing low-coupon notes elevates annual corporate interest expense. Elevated debt service absorbs operating cash flow, restricts aggressive share repurchases, and slows balance-sheet deleveraging. Expected impact: -12%.
Next-generation oral immunology competition: Emerging oral small molecules, including rival oral IL-23 antagonists and TYK2 inhibitors, challenge Skyrizi's and Rinvoq's frontline market dominance in mild-to-moderate autoimmune diseases. Convenient oral alternatives incentivize pharmacy benefit managers to demand steeper rebate concessions to preserve formulary exclusivity. This competitive pressure threatens core biologic pricing power and compresses net realized immunology margins. Expected impact: -11%.
Discretionary aesthetics consumer volume deceleration: The Allergan aesthetics portfolio, anchored by Botox Cosmetic and Juvederm, relies heavily on out-of-pocket discretionary consumer spending. Under persistent macroeconomic inflation and high borrowing costs, elective cosmetic procedures face recurring volume slowdowns and price sensitivity. Subdued aesthetic demand removes an auxiliary high-margin growth driver that historically cushioned pharmaceutical patent transitions. Expected impact: -7%.

Tail risks

Oral IL-23 clinical market disruption: Pivotal Phase 3 data demonstrating that competing oral IL-23 receptor antagonists achieve mucosal healing and skin clearance comparable to Skyrizi without injection burdens would trigger rapid patient substitution. Commercial payers would mandate cheaper oral step-therapy, dismantling AbbVie's premium biologic pricing moat and eliminating billions in projected peak revenues. Probability: +33%. Expected impact: -23%.
Accelerated statutory commercial price controls: Federal legislative escalation accelerating the Medicare negotiation calendar or expanding statutory price caps to private commercial insurance would severely impair U.S. biopharma economics. Stripping commercial pricing flexibility from Skyrizi and Rinvoq would cause immediate double-digit gross margin contraction, forcing dividend growth pauses and violent equity de-rating. Probability: +27%. Expected impact: -22%.

Tail opportunities

Apogee next-generation antibody trial triumph: Phase 3 clinical validation of Apogee's APG777 demonstrating superior efficacy and extended quarterly or twice-yearly dosing in atopic dermatitis would validate the $10.9 billion acquisition. Unlocking a differentiated multi-billion-dollar non-JAK dermatology franchise would extend AbbVie's immunology moat well beyond 2035, pulling forward earnings accretion and driving substantial valuation multiple expansion. Probability: +34%. Expected impact: +21%.
Tavapadon Parkinson registrational label sweep: Comprehensive FDA and European regulatory approval of Cerevel-derived tavapadon across early and advanced Parkinson's disease would unlock an unaddressed multi-billion-dollar movement disorder market. Commercial scaling alongside Vyalev would salvage deal economics from prior clinical impairments, expanding group operating cash flow and driving upward revisions to outer-year corporate earnings. Probability: +36%. Expected impact: +16%.

What to monitor

Thesis watchpoints

-- Combined Skyrizi and Rinvoq quarterly net sales exceeding $8.5 billion through mid-2027, confirming commercial market share durability.

Key insights

Consolidated gross margins compressing below 68% across consecutive quarters, signaling aggressive payer rebate extraction and statutory pricing erosion.
Center for Medicare and Medicaid Services naming Rinvoq in statutory price negotiation lists, forcing immediate terminal valuation multiple reassessment.

Company Financial Analysis

AbbVie Earnings and Financials Analysis by AI

Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

AbbVie's financial results tell an impressive story of business recovery. After facing the loss of patent exclusivity on Humira, the company successfully replaced lost sales with rapid double-digit growth from Skyrizi and Rinvoq, pushing twelve-month revenues to $64.4 billion. Together with a solid neuroscience division, core prescription demand has decisively rebounded. However, headline accounting earnings can be confusing. Reported net income of $6.31 billion looks modest because of heavy accounting write-downs and amortization from past corporate mergers. In reality, AbbVie generated approximately $18.2 to $19.7 billion in trailing free cash flow, proving that day-to-day operational cash generation remains exceptionally strong.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2025	USD 61.2B	USD 4.2B	USD 17.8B
2024	USD 56.3B	USD 4.3B	USD 17.8B
2023	USD 54.3B	USD 4.9B	USD 22.1B
2022	USD 58.1B	USD 11.8B	USD 24.2B
2021	USD 56.2B	USD 11.5B	USD 22B

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2025	95.9x	TTM	Native	USD / USD
2024	73.6x	TTM	Native	USD / USD
2023	56.5x	TTM	Native	USD / USD
2022	24.3x	Annual	Native	USD / USD
2021	20.9x	Annual	Native	USD / USD

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

AbbVie enjoys world-class profit margins on the medicines it sells, posting gross margins above 70% and adjusted gross margins near 85%. Operating margins rebounded sharply to 32.8% as one-off merger charges subsided, demonstrating that manufacturing high-volume biologics like Skyrizi generates tremendous operating leverage. Looking ahead, maintaining these elite margins will become harder. While manufacturing efficiencies remain strong, government drug price negotiations under Medicare Part D and rising insurance rebates will chip away at realized prices. Strong prescription volume will help cushion the blow, but statutory price caps will likely prevent profit margins from expanding much further.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2025	USD 20.1B	32.8%	6.9%
2024	USD 9.1B	16.2%	7.6%
2023	USD 12.8B	23.5%	9.0%
2022	USD 18.1B	31.2%	20.4%
2021	USD 17.9B	31.9%	20.5%

Balance sheet and leverage

AI Review

On paper, AbbVie's balance sheet looks alarming because it reports negative shareholder equity of -$3.23 billion. This negative number is primarily an accounting artifact caused by decades of debt-funded acquisitions and aggressive share buybacks, rather than commercial insolvency. Nevertheless, real balance-sheet risks exist around debt. The company carries over $60 billion in gross debt obligations. With market interest rates hovering near 5%, refinancing old loans will become steadily more expensive. Fortunately, nearly $20 billion in annual free cash flow easily covers debt interest and the $11.7 billion dividend, but debt service leaves less room for extra share repurchases.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2025	USD 69.1B	USD 5.3B	USD 63.8B net debt	0.67x
2024	USD 67.8B	USD 5.6B	USD 62.3B net debt	0.66x
2023	USD 60.1B	USD 12.8B	USD 47.3B net debt	0.87x
2022	USD 64.2B	USD 9.2B	USD 55B net debt	0.96x
2021	USD 77.6B	USD 9.8B	USD 67.8B net debt	0.79x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

AbbVie runs a very asset-light operation when it comes to physical factories, spending less than 2% of annual sales on buildings and equipment. This capital-light structure means the company does not need to pour billions into concrete plants, freeing up massive amounts of cash for shareholders. Instead, real capital spending happens through scientific research and multibillion-dollar corporate takeovers. Management invested over $9 billion in internal R&D in 2025 and committed $10.9 billion in cash to acquire Apogee Therapeutics in September 2026. Because these acquired drug pipelines will not generate significant profits until the 2030s, shareholders are funding expensive bets today that will take years to pay back.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2025	USD 1.2B	USD 9.1B
2024	USD 974M	USD 12.8B
2023	USD 777M	USD 7.7B
2022	USD 695M	USD 6.5B
2021	USD 787M	USD 8B

Immutable published data

Averaged consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	NEUTRAL	68	+7.3%	Not available	ORIGINAL
5Y	NEUTRAL	82	+41.5%	Not available	ORIGINAL

Averaged consensus scenarios

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	December 18, 2026	253.4	267.35	274.52	14
+6M	March 18, 2027	248.33	268.18	280.01	14
+9M	June 18, 2027	253.43	274.3	288.41	14
+1Y	September 18, 2027	255.96	276.23	294.18	14
+15M	December 18, 2027	250.84	280.06	305.94	14
+18M	March 18, 2028	240.81	279.43	309	14
+21M	June 18, 2028	245.63	285.84	318.27	14
+2Y	September 18, 2028	238.26	287.78	324.64	14
+27M	December 18, 2028	233.49	292.24	334.38	14
+30M	March 18, 2029	231.16	293.99	337.72	14
+33M	June 18, 2029	238.09	300.27	347.85	14
+3Y	September 18, 2029	233.33	302.56	354.81	14
+39M	December 18, 2029	231	307.49	365.46	14
+42M	March 18, 2030	224.07	308.16	369.11	14
+45M	June 18, 2030	228.55	314.1	376.49	14
+4Y	September 18, 2030	230.83	316.81	384.02	14
+51M	December 18, 2030	226.22	320.46	391.7	14
+54M	March 18, 2031	230.74	321.82	395.62	14
+57M	June 18, 2031	233.05	325.78	403.53	14
+5Y	September 18, 2031	237.71	329.16	411.6	14

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 761.69 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	723.6055	750.2647	769.3069
+6M	March 18, 2027	701.8973	736.44	784.693
+9M	June 18, 2027	695.1	743.3975	808.2338
+1Y	September 18, 2027	681.198	755.1476	816.3162
+15M	December 18, 2027	688.01	776.2182	840.8057
+18M	March 18, 2028	701.7702	787.1259	857.6218
+21M	June 18, 2028	722.8233	802.8344	883.3504
+2Y	September 18, 2028	730.0515	812.0465	892.1839
+27M	December 18, 2028	751.9531	839.1839	927.8713
+30M	March 18, 2029	766.9921	850.5008	946.4287
+33M	June 18, 2029	782.332	872.3935	965.3573
+3Y	September 18, 2029	790.1553	885.5111	975.0109
+39M	December 18, 2029	805.9584	909.5618	1,004.2612
+42M	March 18, 2030	822.0776	916.132	1,024.3464
+45M	June 18, 2030	830.2984	936.5109	1,055.0768
+4Y	September 18, 2030	830.2984	947.3438	1,065.6276
+51M	December 18, 2030	855.2073	969.5876	1,097.5964
+54M	March 18, 2031	872.3114	979.9863	1,119.5483
+57M	June 18, 2031	889.7577	999.6043	1,141.9393
+5Y	September 18, 2031	898.6553	1,011.7644	1,153.3587

The Anthropologist

Gemini 3.8 Flash

Weight5.5/100

Strong articulation of therapeutic demand inelasticity and cash generation, but exhibits overly bullish multiple expansion expectations that downplay statutory Medicare pricing concessions and debt refinancing burdens.

AI RESEARCHER

Niccolo Machiavelli AI

The Insider

Gemini 3.8 Flash

Weight5.5/100

Provides sharp insight into PBM rebate walls and commercial contracting power, but models an aggressive 40% cumulative return path that discounts impending statutory pricing mandates and acquired-pipeline dilution.

AI THINKER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight4.5/100

Highlights negative book equity and debt refinancing frictions effectively, but adopts an excessively punitive macro multiple compression path that fails to account for biological demand inelasticity and organic cash conversion.

AI RESEARCHER

J.P. Morgan AI

The Titan

Gemini 3.8 Flash

Weight4.5/100

Vivid depiction of commercial fortress contracting and neuroscience scaling, but projects an extreme 55% return path driven by aggressive multiple expansion that dismisses high interest rates and regulatory price caps.

AI RESEARCHER

Michael Burry AI

The Vulture

Gemini 3.8 Flash

Weight3.6/100

Thorough balance sheet forensics exposing negative tangible equity and acquisition risks, but projects an excessively pessimistic negative cumulative return path that underweights commercial fortress moats and dividend coverage durability.

Skip to references

Research Provenance

References & Context

This AbbVie consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Independent AI Advisor panel

AI Advisors: 14
AI Researchers: 11
AI Thinkers: 3

Sources retained from AI Researcher searches

Asset-specific · Researcher web

Showing the top 15 of 81 deduplicated sources retained for this batch.

01Fact Sheet: Medicare Drug Price Negotiation Program June 2023cms.gov
02Selected Drugs and Negotiated Prices | CMScms.gov
03AbbVie Inc. - Form 8-K - FY2026sec.gov
04AbbVie Inc. - Form 8-K - FY2026sec.gov
05Fact Sheet: President Donald J. Trump Announces Deal with Nine Additional Pharmaceutical Manufacturers to Lower Drug Prices for Americans – The White Housewhitehouse.gov
06AbbVie Inc Earnings - Analysis & Highlights for Q2 2026alpha-sense.com
07Medicare Drug Rebate and Negotiations Groupamcp.org
08CMS Releases Third List of Drugs for Medicare Price Negotiation, Including Seven Biologics — Venable's BiologicsHQbiologicshq.com
09AbbVie to Acquire Apogee Therapeutics for $10.9 Billion, Gaining IL-13 Antibody Zumilokibart | BioPharm Internationalbiopharminternational.com
10AbbVie Q2 2026 Earnings Show Double-Digit Growth as Skyrizi, Rinvoq Surge and Apogee Deal Unveiledbiotechreality.com
11IRA update: CMS names 15 drugs for Medicare price negotiation beginning in 2028cardinalhealth.com
12Trump Administration Imposes Section 232 Tariffs on Patented Pharmaceutical Imports; Tiered Rate Structure Takes Effect Beginning July 31, 2026 | Crowell & Moring LLPcrowell.com
13Cerevel Therapeuticsen.wikipedia.org
14[ABBV Q1 2026 Earnings Call] AbbVie Smashes Q1 Expectations, Raises Full-Year Outlook as Skyrizi and Rinvoq Power 12.4% Revenue Surge — BigGo Financefinance.biggo.com
15AbbVie Inc (ABBV) (Q2 2026) Earnings Call Highlights: Robust Growth Driven by Skyrizi and ...finance.yahoo.com

And 66 more sources were used and retained in the batch inventory.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market and World-Events Context Through September 20

Download Archived Snapshot

Coverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20

January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.

Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.

Top 3 market shifts from 2026 Year-to-Date Global Market and World-Events Context Through September 20
Top 3 Market Shifts From File	Date	Status
Renewed monetary tightening amid persistent inflation	2026-01-30	ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption	2026-02-28	ONGOING
Tariff legal reset and strategic supply restrictions	2026-02-20	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics European Central Bank International Monetary Fund Reuters World Associated Press World News

And more sources from the retained context package.

Fundamental context

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

12 fields

cash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields

Cash flow

5 fields

capitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field

annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods

Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.